Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Chemoradiotherapy as Neoadjuvant Therapy for ESCC
NCT07595770Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Pathological Complete Response. Started May 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07595770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595770.